Assessment of the feed additive consisting of Limosilactobacillus fermentum NCIMB 30169 for all animal species for the renewal of its authorisation (Microferm Ltd.)

Abstract Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application of renewal of Limosilactobacillus fermentum NCIMB 30169 as a technological feed additive (functional group: silage additives) for all animal species. The app...

Full description

Saved in:
Bibliographic Details
Main Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Maryline Kouba, Marta López‐Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Roberto Edoardo Villa, Ruud Woutersen, Maria Saarela, Montserrat Anguita, Nicole Bozzi Cionci, Rosella Brozzi, Yolanda García‐Cazorla, Matteo Lorenzo Innocenti, Joana Revez
Format: Article
Language:English
Published: Wiley 2024-05-01
Series:EFSA Journal
Subjects:
Online Access:https://doi.org/10.2903/j.efsa.2024.8794
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application of renewal of Limosilactobacillus fermentum NCIMB 30169 as a technological feed additive (functional group: silage additives) for all animal species. The applicant has provided evidence that the additive currently on the market complies with the existing terms of the authorisation. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) concluded that the additive remains safe for all animal species, consumers, and the environment. Regarding user safety, the additive should be considered a skin and respiratory sensitiser. No conclusions can be drawn on the eye irritancy potential of the additive. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
ISSN:1831-4732